GISC protocol experience in the treatment of essential mixed cryoglobulinaemia

Clin Exp Rheumatol. 1995 Nov-Dec:13 Suppl 13:S187-90.

Abstract

Objective: We compared the efficacy of interferon and deflazacort in the treatment of the cryoglobulinaemic syndrome and assessed the usefulness of adding a low antigen diet to drug therapy.

Methods: We studied 63 patients randomly allocated to different groups who underwent clinical and laboratory examinations every two months and who received treatment for 12 months or until a significant clinical event appeared.

Results: Five of 28 patients treated with interferon showed clinical improvement whereas 4 worsened and 7 suffered untoward side effects; seven of 28 patients treated with deflazacort improved, 4 worsened and 4 suffered drug toxicity. Twenty-nine patients were assigned to combined low antigen diet and therapy, among whom 7 did not follow the diet, 5 improved and 2 worsened. Among the 34 patients who were on an unrestrained diet, 5 improved and 7 worsened. None of the treatments proved superior to the others.

Conclusion: Our results do not confirm the suggestion that interferon should be the primary therapy in the treatment of the cryoglobulinaemic syndrome, and the usefulness of a low antigen diet seems minimal.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents / therapeutic use*
  • Antigens / administration & dosage
  • Combined Modality Therapy
  • Cryoglobulinemia / diet therapy
  • Cryoglobulinemia / therapy*
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Pregnenediones / therapeutic use*
  • Recombinant Proteins

Substances

  • Anti-Inflammatory Agents
  • Antigens
  • Interferon alpha-2
  • Interferon-alpha
  • Pregnenediones
  • Recombinant Proteins
  • deflazacort